Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer

Krimphove, Marieke J.; Cole, Alexander P.; Fletcher, Sean A.; Harmouch, Sabrina S.; Berg, Sebastian; Lipsitz, Stuart R.; Sun, Maxine; Nabi, Junaid; Nguyen, Paul L.; Hu, Jim C.; Kibel, Adam S.; Choueiri, Toni K.; Kluth, Luis A.

doi:10.1038/s41391-018-0083-4

Cited by 67 publications

(48 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with T3 or T4 stage are also known as locally advanced prostate cancer. Krimphove et al reported that PCa with T3 or T4 had a worse overall survival [27]. Meanwhile, the Gleason score is the sum of the two most common grade patterns in PCa, which act as the single most potent predictor of PCa outcomes [28].…”

Section: Discussionmentioning

confidence: 99%

Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients

Jiang

Luo

et al. 2020

J Transl Med

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) is one of the most prevalent cancers that occur in men worldwide. Autophagyrelated genes (ARGs) may play an essential role in multiple biological processes of prostate cancer. However, ARGs expression signature has rarely been used to investigate the association between autophagy and prognosis in PCa. This study aimed to identify and assess prognostic ARGs signature to predict overall survival (OS) and disease-free survival (DFS) in PCa patients. Methods: First, a total of 234 autophagy-related genes were obtained from The Human Autophagy Database. Then, differentially expressed ARGs were identified in prostate cancer patients based on The Cancer Genome Atlas (TCGA) database. The univariate and multivariate Cox regression analysis was performed to screen hub prognostic ARGs for overall survival and disease-free survival, and the prognostic model was constructed. Finally, the correlation between the prognostic model and clinicopathological parameters was further analyzed, including age, T status, N status, and Gleason score. Results: The OS-related prognostic model was constructed based on the five ARGs (FAM215A, FDD, MYC, RHEB, and ATG16L1) and significantly stratified prostate cancer patients into high-and low-risk groups in terms of OS (HR = 6.391, 95% CI = 1.581-25.840, P < 0.001). The area under the receiver operating characteristic curve (AUC) of the prediction model was 0.84. The OS-related prediction model values were higher in T3-4 than in T1-2 (P = 0.008), and higher in Gleason score > 7 than ≤ 7 (P = 0.015). In addition, the DFS-related prognostic model was constructed based on the 22 ARGs (ULK2,

show abstract

Section: Discussionmentioning

confidence: 99%

Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients

Jiang

Luo

et al. 2020

J Transl Med

View full text Add to dashboard Cite

show abstract

“…In fact, in that analysis, black race was associated with better overall survival. 3 Data from several clinical trials point in the same direction. George et al 16 reported that black men had better a progression-free survival rate compared with white men (16.6 months vs 11.5 months) when treated with abiraterone and prednisone.…”

Section: Discussionmentioning

confidence: 93%

“…2,4 Additionally, we found that when patient and sociodemographic factors are taken into account, the differences were actually reversed, that is, black men may have had better survival than white men. 3 Taken together, these findings may provide more evidence of a racial disparity, suggesting a form of social injustice rather than racial difference attributable to biology.…”

Section: Introductionmentioning

confidence: 88%

Geographic Distribution of Racial Differences in Prostate Cancer Mortality

et al. 2020

Self Cite

View full text Add to dashboard Cite

IMPORTANCE While racial disparities in prostate cancer mortality are well documented, it is not well known how these disparities vary geographically within the US. OBJECTIVE To characterize geographic variation in prostate cancer-specific mortality differences between black and white men. DESIGN, SETTING, AND PARTICIPANTS This cohort study included data from 17 geographic registries within the Surveillance, Epidemiology, and End Results (SEER) database from January 1, 2007, to December 31, 2014. Inclusion criteria were men 18 years and older with biopsy-confirmed prostate cancer. Men missing data on key variables (ie, cancer stage, Gleason grade group, prostatespecific antigen level, and survival follow-up data) were excluded. Analysis was performed from September 5 to December 25, 2018. EXPOSURE Patient SEER-designated race (ie, black, white, or other). MAIN OUTCOMES AND MEASURES Fine and Gray competing-risks regression analyses were used to evaluate the difference in prostate-cancer specific mortality between black and white men. A stratified analysis by Gleason grade group was performed stratified as grade group 1 and grade groups 2 through 5. RESULTS The final cohort consisted of 229 771 men, including 178 204 white men (77.6%), 35 006 black men (15.2%), and 16 561 men of other or unknown race (7.2%). Mean (SD) age at diagnosis was 64.9 (8.8) years. There were 4773 prostate cancer deaths among white men and 1250 prostate cancer deaths among black men. Compared with white men, black men had a higher risk of mortality overall (adjusted hazard ratio [AHR], 1.39 [95% CI, 1.30-1.48]). In the stratified analysis, there were 4 registries in which black men had worse prostate cancer-specific survival in both Gleason grade

show abstract

“…In more recent literature, the impact of genomic differences by race has been found to be relatively small and limited to patients with lower Gleason scores (3). The vast majority of racial disparity between black and nonblack patients appears to be driven by socioeconomic factors such as access to care (4), and racial differences in prostate cancerespecific mortality which is most pronounced among men with Gleason 6 disease (5). Furthermore, racial disparities persist in the utilization of brachytherapy which is an effective and commonly used treatment modality for men with low-risk disease (6).…”

Section: Introductionmentioning

confidence: 99%

Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: Evidence from the Department of Veterans Affairs

2020

View full text Add to dashboard Cite

PURPOSE: African American men have historically had poorer prostate cancer biochemical and survival outcomes than Caucasians. However, emerging data suggest nononcologic factors drive much of this disparity. Prior evidence has suggested an association between a transient prostate specific antigen (PSA) bounce and improved biochemical control. However, racial differences in this relationship have remained relatively unexplored. METHODS AND MATERIALS: We identified 4477 men treated for low-or intermediate-risk prostate cancer within the U.S. Department of Veterans Affairs (VA) from 2000 to 2010 with brachytherapy alone or in combination with external beam radiotherapy without androgen deprivation. Longitudinal PSA data were used to define to biochemical failure and PSA bounce. Cox proportional hazard models were used explore racial differences in the relationship between the PSA bounce and time to biochemical failure. RESULTS: Thirty-one percent of our sample experienced a PSA bounce, with African Americans more likely to experience a bounce (42%) compared with Caucasians (29%); p !0.001. Despite this, African Americans had a higher likelihood of biochemical failure (hazard ratio [HR] 1.4; p 5 0.006). However, African American men experiencing a PSA bounce were less likely to experience a biochemical failure (HR 5 0.64; p 5 0.046), whereas this relationship was not statistically significant for Caucasians (HR 5 0.78; p 5 0.092). On multivariate analysis, African Americans receiving brachytherapy alone were most sensitive to the protective benefit of the PSA bounce (HR 5 0.64). CONCLUSIONS: A PSA bounce was associated with improved biochemical control among patients receiving brachytherapy as part of their treatment for low-or intermediate-risk prostate cancer at the VA. African American men treated with brachytherapy had a particularly pronounced biochemical control benefit of a PSA bounce.

show abstract

Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer

Cited by 67 publications

References 33 publications

Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients

Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients

Geographic Distribution of Racial Differences in Prostate Cancer Mortality

Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: Evidence from the Department of Veterans Affairs

Contact Info

Product

Resources

About